id,content,title,publisher,url,publishedAt,symbols,description
e7803b46-1359-3be1-9a22-efff0f1705ac,"{'id': 'e7803b46-1359-3be1-9a22-efff0f1705ac', 'contentType': 'STORY', 'title': 'Private equity GTCR strikes $4.8 billion deal to buy Zentiva, FT reports', 'description': '', 'summary': 'Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drugmaker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unidentified sources. Reuters could not immediately confirm the report. GTCR, Advent and Zentiva did not immediately respond to a Reuters request for comment.', 'pubDate': '2025-09-11T03:39:06Z', 'displayTime': '2025-09-11T03:39:06Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': {'originalUrl': 'https://media.zenfs.com/en/reuters.com/6ffb913d75af503b4206c36386938384', 'originalWidth': 800, 'originalHeight': 495, 'caption': 'FILE PHOTO: A logo of pharmaceutical company Zentiva is seen outside the Zentiva factory in Prague, Czech Republic, May 6, 2021. Picture taken May 6, 2021.   REUTERS/David W Cerny/File Photo', 'resolutions': [{'url': 'https://s.yimg.com/uu/api/res/1.2/4SbQj683WeonuaQmA7xzeQ--~B/aD00OTU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6ffb913d75af503b4206c36386938384', 'width': 800, 'height': 495, 'tag': 'original'}, {'url': 'https://s.yimg.com/uu/api/res/1.2/5fFjz9ufN_R9IjPSmLnYPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6ffb913d75af503b4206c36386938384', 'width': 170, 'height': 128, 'tag': '170x128'}]}, 'provider': {'displayName': 'Reuters', 'url': 'https://www.reuters.com/'}, 'canonicalUrl': {'url': 'https://ca.finance.yahoo.com/news/private-equity-gtcr-strikes-4-033906768.html', 'site': 'finance', 'region': 'CA', 'lang': 'en-CA'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/private-equity-gtcr-strikes-4-033906768.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
fbb96334-ea2e-310a-9fd5-2bb5b1edb819,"{'id': 'fbb96334-ea2e-310a-9fd5-2bb5b1edb819', 'contentType': 'STORY', 'title': ""India's Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports"", 'description': '', 'summary': ""Aurobindo is in talks with Zentiva's owner U.S.-based private equity firm Advent International, the report said, citing people aware of the matter.  However, Aurobindo, in a statement to exchanges, said no binding agreements have been signed by the company's board.  Advent International and Zentiva declined to comment on the report."", 'pubDate': '2025-08-20T06:50:52Z', 'displayTime': '2025-08-20T06:50:52Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': {'originalUrl': 'https://media.zenfs.com/en/reuters.com/dddd5a31d5892719e9b6a99b1c7debdd', 'originalWidth': 800, 'originalHeight': 551, 'caption': ""Central Europe's drugmakers catching the eye of international investors"", 'resolutions': [{'url': 'https://s.yimg.com/uu/api/res/1.2/bZtH4KiAoNWIigby8Sz_6w--~B/aD01NTE7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/dddd5a31d5892719e9b6a99b1c7debdd', 'width': 800, 'height': 551, 'tag': 'original'}, {'url': 'https://s.yimg.com/uu/api/res/1.2/pHrh0fUxI_lFFDxkzfbDKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/dddd5a31d5892719e9b6a99b1c7debdd', 'width': 170, 'height': 128, 'tag': '170x128'}]}, 'provider': {'displayName': 'Reuters', 'url': 'https://www.reuters.com/'}, 'canonicalUrl': {'url': 'https://sg.finance.yahoo.com/news/indias-aurobindo-pharma-leads-race-065052905.html', 'site': 'finance', 'region': 'SG', 'lang': 'en-SG'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/indias-aurobindo-pharma-leads-race-065052905.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
f31f1950-6c6c-33b9-b0ec-d3cd7447bf9b,"{'id': 'f31f1950-6c6c-33b9-b0ec-d3cd7447bf9b', 'contentType': 'STORY', 'title': 'Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion', 'description': '', 'summary': 'Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 17, Morgan Stanley upgraded FOLD to Overweight with a $12 price target, citing its strong intellectual property position ahead of a key legal decision with Aurobindo. The firm also pointed to Amicus’s solid financials—including a […]', 'pubDate': '2025-07-25T03:47:45Z', 'displayTime': '2025-07-25T03:47:45Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': {'originalUrl': 'https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf', 'originalWidth': 1456, 'originalHeight': 816, 'caption': 'Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion', 'resolutions': [{'url': 'https://s.yimg.com/uu/api/res/1.2/d.G1BwOHpKPHkwYFPwVtyQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf', 'width': 1456, 'height': 816, 'tag': 'original'}, {'url': 'https://s.yimg.com/uu/api/res/1.2/0GDZ2zhEkX4VDgAedBA.FQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/89f6be1da850b22042e3702894fcf9bf', 'width': 170, 'height': 128, 'tag': '170x128'}]}, 'provider': {'displayName': 'Insider Monkey', 'url': 'http://www.insidermonkey.com'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/morgan-stanley-upgrades-amicus-fold-034745699.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/morgan-stanley-upgrades-amicus-fold-034745699.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
e09d63c8-3ead-3215-b79f-5a03f2631fea,"{'id': 'e09d63c8-3ead-3215-b79f-5a03f2631fea', 'contentType': 'STORY', 'title': ""Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug"", 'description': '', 'summary': 'Acadia Pharmaceuticals (ACAD) late Monday said the US Court of Appeals for the Federal Circuit has u', 'pubDate': '2025-06-09T21:53:25Z', 'displayTime': '2025-06-09T21:53:25Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'MT Newswires', 'url': 'https://www.mtnewswires.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/acadia-pharmaceuticals-again-prevails-appeal-215325957.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/acadia-pharmaceuticals-again-prevails-appeal-215325957.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': True, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
679b9bee-5267-3985-ac0d-01a16fe4258a,"{'id': '679b9bee-5267-3985-ac0d-01a16fe4258a', 'contentType': 'STORY', 'title': 'Aurobindo Pharma Ltd (BOM:524804) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...', 'description': '', 'summary': 'Aurobindo Pharma Ltd (BOM:524804) reports robust financial performance with significant growth in European and specialty segments, despite challenges in key markets.', 'pubDate': '2025-05-28T07:00:46Z', 'displayTime': '2025-05-28T07:00:46Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'GuruFocus.com', 'url': 'http://www.gurufocus.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/aurobindo-pharma-ltd-bom-524804-070046429.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/aurobindo-pharma-ltd-bom-524804-070046429.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
e8532d2d-4a81-30cf-ab94-42363412e217,"{'id': 'e8532d2d-4a81-30cf-ab94-42363412e217', 'contentType': 'STORY', 'title': 'Aurobindo Pharma Ltd (BOM:524804) Q3 2025 Earnings Call Highlights: Record Revenue and ...', 'description': '', 'summary': 'Aurobindo Pharma Ltd (BOM:524804) reports its highest ever quarterly revenue, driven by strong US and European sales, while navigating operational challenges and market pressures.', 'pubDate': '2025-02-08T07:00:40Z', 'displayTime': '2025-02-08T07:00:40Z', 'isHosted': True, 'bypassModal': False, 'previewUrl': None, 'thumbnail': None, 'provider': {'displayName': 'GuruFocus.com', 'url': 'http://www.gurufocus.com/'}, 'canonicalUrl': {'url': 'https://finance.yahoo.com/news/aurobindo-pharma-ltd-bom-524804-070040732.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'clickThroughUrl': {'url': 'https://finance.yahoo.com/news/aurobindo-pharma-ltd-bom-524804-070040732.html', 'site': 'finance', 'region': 'US', 'lang': 'en-US'}, 'metadata': {'editorsPick': False}, 'finance': {'premiumFinance': {'isPremiumNews': False, 'isPremiumFreeNews': False}}, 'storyline': None}",N/A,N/A,N/A,N/A,N/A,N/A
